Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD

Overview

The purpose of this study is to compare acute bronchodilator effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI and Salbutamol 100 mcg Inhaler (2 inhalations) plus Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination in Patients with stable moderate-severe-very severe COPD.

Full Title of Study: “Comparison of Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination Delivered Via pMDI and Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol in Patients With Stable Moderate-Severe-Very Severe Chronic Obstructive Pulmonary Disease (COPD).”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2021

Interventions

  • Drug: Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
    • Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
  • Drug: Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
    • Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).

Arms, Groups and Cohorts

  • Experimental: Ipratropium/Levosalbutamol
    • Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
  • Active Comparator: Salbutamol + Ipratropium
    • Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI

Clinical Trial Outcome Measures

Primary Measures

  • FEV1 AUC (0-8h)
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h. Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.

Secondary Measures

  • FEV1 AUC (0-4h)
    • Time Frame: Baseline, 0 to 4 hours post-dose at treatment day
    • Change From Baseline in FEV1 AUC (0-4h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FEV1 AUC (4-6h)
    • Time Frame: Baseline, 4 to 6 hours post-dose at treatment day
    • Change From Baseline in FEV1 AUC (4-6h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FEV1 AUC (6-8h)
    • Time Frame: Baseline, 6 to 8 hours post-dose at treatment day
    • Change From Baseline in FEV1 AUC (6-8h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FVC AUC (0-4h)
    • Time Frame: Baseline, 0 to 4 hours post-dose at treatment day
    • Change From Baseline in Forced Vital Capacity (FVC) AUC (0-4h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FVC AUC (4-6h)
    • Time Frame: Baseline, 4 to 6 hours post-dose at treatment day
    • Change From Baseline in FVC AUC (4-6h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FVC AUC (6-8h)
    • Time Frame: Baseline, 6 to 8 hours post-dose at treatment day
    • Change From Baseline in FVC AUC (6-8h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • FVC AUC (0-8h)
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Change From Baseline in FVC AUC (0-8h). Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • Change From Baseline in FEV1 and FVC within the first 15 minutes after dosing
    • Time Frame: Baseline, 0 to 15 minutes post-dose at treatment day
    • Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • Mean Maximum Change From Baseline in FEV1 and FVC within the first 2 hours after dosing
    • Time Frame: Baseline, 0 to 2 hours post-dose at treatment day
    • Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • The Time to Onset of Bronchodilator Response
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Bronchodilator response is defined as 100 mL improvement in FEV1. Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • The Time to Maximum Effect
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • Duration of Bronchodilator Response
    • Time Frame: Baseline, 0 to 8 hours post-dose at treatment day
    • Bronchodilator response is defined as 100 mL improvement in FEV1. Spirometric measurements will be performed pre-treatment and 5 min, 15 min, 30 min, 45 min and 1 h, 2 h, 3 h, 4 h, 5 h, 6h, 7h, 8h after drug administration.
  • Evaluation of Safety (physical examination, numbers of adverse reactions and abnormal laboratory values or ECG related to treatment)
    • Time Frame: Baseline, 0 to 24 hours post-dose

Participating in This Clinical Trial

Inclusion Criteria

  • Female and male patients aged ≥40 years diagnosed with symptomathic stable moderate-severe-very severe COPD: post-bronchodilator FEV1/FVC <70% predicted and a post-bronchodilator FEV1 <80% predicted at screen visit.

Group B COPD CAT: ≥10 or mMRC: ≥ 2 Exacerbation: 0-1 (not leading to hospital admission)

Group C COPD CAT: <10 or mMRC: 0-1 Exacerbation: ≥2 (not leading to hospital admission) or ≥1 (leading to hospital admission)

Group D COPD CAT: ≥10 or mMRC: ≥ 2 Exacerbation: ≥2 (not leading to hospital admission) or ≥1 (leading to hospital admission)

  • Current or ex-smokers with a smoking history of at least 10 pack-years
  • Patients who have no exacerbation within the last 4 weeks
  • Female patients who use effective contraception
  • Patients who have a capability to communicate with investigator
  • Patients who accept to comply with the protocol
  • Patients who sign written informed consent form

Exclusion Criteria

  • History of hypersensitive to anticholinergics or SABAs
  • History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 4 weeks prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
  • Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit
  • Use of oral corticosteroid at unstable dosages (i.e. <6 weeks on a stable dose of prednisone)
  • SGOT (serum glutamic oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL
  • History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
  • Initiation of an inhaled steroid or change in dose within <6 weeks prior the screening visit
  • Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
  • Recent (within ≤1 year prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment
  • Regularly use of daytime CPAP (continuous positive airway measure) oxygen therapy for longer than 1 hour per day
  • Initiation of pulmonary rehabilitation within the 3 months prior the screening visit
  • History of lung volume reduction surgery
  • Drug or alcohol abuse
  • Presence of active tuberculosis
  • History of atopy or allergic rhinitis
  • History of cancer within the last 5 years
  • Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
  • Pregnancy or lactation
  • Presence of known symptomatic prostatic hypertrophy requiring treatment
  • Presence of known narrow-angle glaucoma requiring treatment
  • Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Neutec Ar-Ge San ve Tic A.Ş
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ismail Hanta, Professor Doctor, Principal Investigator, Cukurova University Faculty of Medicine, Chest Diseases Department Adana – Turkey
    • Hakan Gunen, Professor Doctor, Principal Investigator, Sureyyapasa Training and Research Center for Chest Diseases and Thoracic Surgery, Maltepe, Istanbul – Turkey
  • Overall Contact(s)
    • Neutec R&D, +90 505 174 7901, esrakorkmaz@neutecrdc.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.